1 min read
Add as a preferred source on Google

MaxCyte Preliminary Q3 Core Revenue Rises 26% to About $8.1 Million

The preliminary figure covers MaxCyte’s core business for the third quarter of 2026.

A laboratory vessel beside a compact cell-engineering instrument / TokenPost.ai
A laboratory vessel beside a compact cell-engineering instrument / TokenPost.ai

MaxCyte’s preliminary core business revenue rose 26% year over year to about $8.1 million in the third quarter of 2026.

The revenue figure is preliminary and covers MaxCyte’s core business.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…